Biopharma AI
By
How Did Roche’s 2025 Deals Shape Its Strategy and Future Outlook?
In 2025, Roche executed a series of focused deals and collaborations designed to strengthen its scientific platforms, expand…
How Did Roche Navigate 2025 and What Lies Ahead for 2026?
Roche concluded 2025 as a company demonstrating resilient performance, strategic focus, and continued innovation across its pharmaceuticals and…
How Did Johnson & Johnson’s 2025 Deals Shape Its Strategy, and What Do They Signal for 2026?
New Brunswick, NJ — In 2025, Johnson & Johnson executed a series of strategic collaborations, acquisitions, and partnerships…
How Did Johnson & Johnson Navigate 2025 and What Lies Ahead for 2026?
Johnson & Johnson concluded 2025 with a combination of resilient portfolio performance, strategic execution, and ongoing innovation across…
Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?
23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex, initiating a strategic…
Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?
23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…
